新的研究发现,Imfinzi大大降低了膀胱癌的复发率,并比化疗提高了存活率。 New study finds Imfinzi significantly cuts bladder cancer recurrence and boosts survival rates over chemotherapy.

一项新的研究表明,接受Imfinzi(durvalumab)免疫疗法药物治疗的膀胱癌患者的癌症复发机率比接受化疗的患者低32%,存活率更高。 A new study shows that bladder cancer patients treated with the immunotherapy drug Imfinzi (durvalumab) had a 32% lower chance of cancer returning and higher survival rates compared to those on chemotherapy. 这项涉及1 063名病人的试验发现,使用Imfinzi的人的两年存活率为82.2%,而其他人的存活率为75.2%。 The trial, involving 1,063 patients, found that two-year survival was 82.2% for those using Imfinzi, compared to 75.2% for others. 研究人员的目标是,如果得到监管机构的批准,该药物将成为新的护理标准。 Researchers aim for the drug to become the new standard of care if approved by regulators.